Gribbon, PhilipPhilipGribbonGeisslinger, GerdGerdGeisslingerZaliani, AndreaAndreaZalianiClaussen, CarstenCarstenClaussen2024-06-262024-06-262022-05-25https://publica.fraunhofer.de/handle/publica/470453The present invention relates to a compound selected from the compounds indicated in Table 1 and pharmaceutically acceptable salts and prodrugs thereof for use in treating and/or preventing a coronavirus infection in a subject; and to compositions, methods, kits, and devices related thereto.enpatentEP4000606 A1EP20200208428